Needham raised the firm’s price target on Taysha Gene Therapies (TSHA) to $10 from $8 and keeps a Buy rating on the shares after the FDA granted breakthrough therapy designation to TSHA-102 for the treatment of Rett syndrome.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Positive Outlook for Taysha Gene Therapies: Buy Rating Affirmed with FDA Support and Breakthrough Designation
- Taysha Gene Therapies Gains FDA Breakthrough Designation
- Taysha Gene Therapies announces FDA BTD to TSHA-102
- Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
- Taysha Gene Therapies’ Earnings Call: Progress Amid Challenges